Comment On: 'Anti-Ro52 Autoantibodies Are Associated with Interstitial Lung Disease and More Severe Disease in Patients with Juvenile Myositis' by Sabbagh Et Al

Zaixing Yang,Yan Liang
DOI: https://doi.org/10.1136/annrheumdis-2019-215678
IF: 27.973
2020-01-01
Annals of the Rheumatic Diseases
Abstract:We read with great interest the article by Sabbagh et al 1 published in the Annals of the Rheumatic Diseases . We congratulate the authors for their accuracy and the exhaustive data presented, which clearly demonstrate the importance of anti-Ro52 autoantibodies in disease monitoring, management and prognosis in patients with juvenile myositis. We would like, however, to highlight some key points. First, in this study,1 the patients with juvenile myositis including juvenile dermatomyositis (JDM), juvenile polymyositis (JPM) and juvenile connective tissue disease–myositis (JCTM) overlap are a highly heterogeneous population. In particular, JCTM added a great heterogeneity to the study population. In reality, there has been still controversy on considering CTM as a distinct entity or rather a complication …
What problem does this paper attempt to address?